Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
patritumab deruxtecan + trastuzumab
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Patritumab deruxtecan + trastuzumab** is a combination regimen consisting of two anticancer monoclonal antibodies. Patritumab deruxtecan is a HER3-directed antibody-drug conjugate (ADC) comprising a fully human anti-HER3 IgG1 monoclonal antibody linked to a cytotoxic payload via a cleavable linker, designed to target and deliver chemotherapy specifically to cells expressing HER3, a member of the EGFR family implicated in tumorigenesis[8][10]. Trastuzumab is a humanized monoclonal antibody that targets HER2, overexpressed in certain cancers, and functions by blocking HER2-mediated signaling and inducing antibody-dependent cytotoxicity[6][9]. This regimen, administered intravenously, is under clinical investigation for advanced breast cancer, especially in settings where HER3 and/or HER2 expression are relevant[4].
- Other names
- patritumab deruxtecan + trastuzumabpatritumab deruxtecan and trastuzumab
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on patritumab deruxtecan + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on patritumab deruxtecan + trastuzumab.